Osteoarthritis
Conditions
Brief summary
Study design: Allocation: Randomized. Endpoint Classification: Comparative Study. Intervention model: Parallel Assignment. Masking: Double Blind (Subject, Assessed) Primary purpose: Comparison. Official Title: Intra-articular hyaluronic acid knee injection: randomized control trail. Primary outcome measures: * Lower extremity functional scale * Visual analogue scale * Range of motion * Kellgren and Lawrence class grade Estimated enrollment: 100 Study start date: December 2012 Estimated study completion date: June 2013 Estimated primary completion date: December 2013
Detailed description
The study include: 200 knees, 50 knees will have single injection of Crespine gel, and 50 knees will have single injection of 2 ampules of Intragel, also 50 knees will have single injection of Crespine plus gel and 50 knees will have single injection of Monovisc The patient will be randomized to Crespine gel or to Intragel, and Crespine Plus gel or to Monovisc Inclusion Criteria: patients with Osteoarthritis grade II and III according to Kellgren and Lawrence grading were included. Exclusion Criteria: patients with autoimmune illnesses, active inflammation or infected processes, anticoagulant, and known allergy to hyaluronic acid. Target parameters: * Lower extremity functional scale * Visual analogue scale * Range of motion * Kellgren and Lawrence class grade Eligibility: Ages Eligible for Study: 20 years to 70 years Genders Eligible for Study: both Accepts Healthy Volunteers: no Criteria Inclusion Criteria: * Age of patients between 20 and 70 years * patients with Osteoarthritis grade II and III according to Kellgren and Lawrence grading Exclusion Criteria: * Autoimmune illnesses * Active inflammation or infected processes * Anticoagulant * Known allergy to hyaluronic acid.
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
* Age of patients between 20 and 70 years * patients with Osteoarthritis grade II and III according to Kellgren and Lawrence grading
Exclusion criteria
* Autoimmune illnesses * Active inflammation or infected processes * Anticoagulant * Known allergy to hyaluronic acid.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lower extremity functional scale | up to 52 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Visual analog scale | up to 52 weeks |
| Kellgren and lawrence class grade | up to 52 weeks |
| Range of motion | up to 52 weeks |
Countries
Egypt